Substances · Cathinone derivatives
3-CMC
- Preferred name
- 3-CMC
- IUPAC name
- 1-(3-chlorophenyl)-2-(methylamino)propan-1-one
- Parent CAS number (reference)
- 1049677-59-9
- Molecular formula
- C10H12ClNO
- Molecular weight
- 197.66 g/mol
- InChIKey
- VOEFELLSAAJCHJ-UHFFFAOYSA-N
- PubChem
- CID 50999285
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
3-Chloromethcathinone Metaclephedrone Clophedrone 3CMC 3 CMC
Verified Neurochemical & Toxicological Intelligence
3-CMC (Clophedrone / 3-Chloromethcathinone)
Receptor Telemetry & Mechanism of Action
Acts as a substrate-type serotonin-norepinephrine-dopamine releasing agent (SNDRA). In rat brain synaptosome assays (Walther et al., 2018), 3-CMC evokes potent release at NET (EC50 = 19 ± 3 nM) and DAT (EC50 = 26 ± 4 nM) alongside moderate serotonin release at SERT (EC50 = 211 ± 33 nM; SERT/DAT EC50 selectivity ratio ~8.1). This meta-chlorinated profile yields brisk, clear-headed dopaminergic mood elevation and talkativeness with noticeably lighter serotonergic heaviness than 4-CMC or 4-MMC.
Biotransformation & Active Metabolites
Human urinary studies identify 9 Phase I/II metabolites via beta-ketone reduction (to beta-OH-3-CMC, enriched after mucosal use), N-demethylation (to 3-chlorocathinone), oral-predominant N-acetylation, carboxylation, and hypothesized N-glucuronidation.
Temporal Pharmacokinetics
Fast-acting, dopaminergic-leaning stimulant-entactogen delivering crisp physical energy, social disinhibition, heightened libido, and moderate emotional warmth over a compact 1–5 hour window.
- Onset 10–30 minutes oral (5–8 minutes mucosal)
- Peak Window 20–120 minutes oral (20–90 minutes mucosal)
- Total Window 1–5 hours oral (commonly 2–4 hours; 1–2 hours mucosal)
- Residual / Half-Life 2–6 hours of residual insomnia, cognitive fatigue, and irritability (up to 12 hours after repeated exposure); formal human plasma half-life is unverified.
Oral response spans 30 mg threshold to 180–250+ mg heavy (mucosal common range is lower at 50–85 mg, with harsh mucosal irritation). Because the primary mood-elevating peak subsides within 20–120 minutes, 3-CMC carries a strong urge to redose; repeated repeated exposure rapidly compounds peripheral vasoconstriction, tachycardia, and acute mid-sentence working-memory suppression without restoring initial mood elevation.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
30 mg (mucosal: 20 mg)
Subtle wakefulness, mild lift in mood and alertness, and slight reduction in social hesitation.
Mild heart-rate elevation, slight dry mouth, and faint peripheral warmth.
30–60 mg (mucosal: 20–50 mg)
Clear sociability, fluent conversation, enhanced music appreciation, and gentle confidence.
Light psychomotor stimulation, mild appetite suppression, and modest pulse increase.
60–100 mg (human observational cohorts up to 100–150 mg; mucosal: 50–85 mg)
Pronounced dopaminergic mood elevation, talkativeness, lowered inhibitions, heightened libido, and strong urge to redose as peak fades.
Marked tachycardia, elevated blood pressure, dilated pupils, sweating, jaw tension, and cool hands or feet from vasoconstriction.
100–180 mg (mucosal: 85–130 mg)
Intense rushing stimulation, scattered focus, short-term memory slips ('fried' cognition after peak), and heightened anxiety during offset.
Pronounced bruxism, tremors, cold/pale extremities, hyperthermia risk in warm venues, and urinary difficulty.
180–250+ mg (mucosal: 130–200+ mg)
Severe confusion, acute panic, paranoid delusions, stimulant psychosis, and disorientation.
Dangerous hypertension, arrhythmias, severe peripheral vasoconstriction, hyperthermia, seizures, pulmonary edema, and potential cardiovascular collapse.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Blocks monoamine breakdown while 3-CMC floods synapses with dopamine, norepinephrine, and serotonin, triggering fatal hypertensive crisis, hyperthermia, and serotonin syndrome.
Synergistic serotonergic overload and seizure-threshold lowering create acute risk of fatal serotonin syndrome, hyperthermia, and tonic-clonic convulsions.
Extreme additive vasoconstriction, adrenergic/cardiac strain, hypertension, seizures, and acute myocardial ischemia.
Elevated Hazard — Avoid
3-CMC heavily masks depressant intoxication while worsening dehydration and cardiac strain; when the short cathinone peak drops off, unopposed CNS depression can cause sudden collapse.
Compounds tachycardia, blood-pressure spikes, bruxism, and post-session anxiety without improving mood.
Caution / Receptor Attenuation
Blunts serotonergic entactogenic warmth at SERT while leaving adrenergic/dopaminergic cardiovascular load intact; high doses still carry serotonin toxicity risk.
Frequently amplifies resting heart rate, thought acceleration, and comedown paranoia.
Structural Isomer & Sibling Comparison
Compared to para-isomer 4-CMC, 3-CMC is ~1.6-fold stronger at releasing dopamine (DAT EC50 26 nM vs. 42.2 nM) and ~1.5-fold weaker at serotonin (SERT EC50 211 nM vs. 144 nM), making 3-CMC sharper, more energetic, and less dreamy/sedating than 4-CMC. Compared to ortho-isomer 2-CMC (DAT EC50 179 nM, SERT 2,815 nM), 3-CMC is ~6.9-fold more potent at DAT and noticeably warmer. Relative to 3-MMC, 3-CMC feels shorter in duration with harsher nasal irritation and steeper cognitive fatigue on repeated exposure.
Physicochemical Stability & Storage
Physical Form: Colorless, white, or pale off-white crystalline powder, translucent shards, or crystalline lumps as the hydrochloride salt (mp ~181–193 °C with decomposition). · Soluble in water, methanol, ethanol, DMF, and DMSO.
Beta-ketone group is vulnerable to oxidative and alkaline degradation in solution; store dry crystals in an airtight, light-protected container at cool or refrigerated temperatures.
Cross-Tolerance & Dependence Profile
Produces rapid acute tachyphylaxis and cross-tolerance with all dopaminergic and serotonergic stimulants (3-MMC, 4-MMC, amphetamines). Acute stimulant tolerance halves in ~3–7 days and resets in 1–2 weeks, though serotonergic recovery warrants multi-week spacing. High psychological dependence liability driven by short duration and compulsive repeated exposure; abrupt cessation after binges causes dysphoria, exhaustion, and anxiety.
Codes on this card
Short meanings for the abbreviations printed with this substance.
DAT
Dopamine transporter
DAT is the protein that collects dopamine back from the gap between nerve cells. A card that names DAT is quoting a laboratory result about that protein.
NET
Norepinephrine transporter
NET is the protein that collects norepinephrine, also called noradrenaline, back into the nerve cell. Cards cite it when a lab report shows activity at that transporter.
SERT
Serotonin transporter
SERT is the protein that collects serotonin back into the nerve cell. A higher number than at DAT means the serotonin transporter needed more concentration to reach the halfway point.
SNDRA / NDRI
Releaser or reuptake blocker
An SNDRA is carried in and the cell releases serotonin, norepinephrine, and dopamine. An NDRI mainly slows the vacuum at norepinephrine and dopamine. The class line says which one the papers describe.
EC₅₀ / IC₅₀
Halfway concentration
EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.
isomer
Isomers
Isomers share the same atoms in the same counts, but the atoms are arranged differently. They can share a molecular formula and still be different chemicals, with different CAS numbers and different lab results.
5-HT ↑↑
Serotonergic Overload (Serotonin Toxicity)
A potentially fatal medical emergency caused by excessive synaptic serotonin (for example when mixing two serotonin releasers, MAOIs, or tramadol), marked by hyperthermia and neuromuscular rigidity.
HR / Naczynia
Vasoconstriction & Cardiovascular Load
Narrowing of peripheral blood vessels, elevated blood pressure, and rapid heart rate driven by strong noradrenergic and dopaminergic stimulation.
Chemical Architecture & Structural Profile
3-CMC (1-(3-chlorophenyl)-2-(methylamino)propan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C10H12ClNO and a molar mass of 197.66 g/mol. The parent molecule is indexed under CAS registry number 1049677-59-9 and in the NCBI PubChem database as CID 50999285 (Standard InChIKey: VOEFELLSAAJCHJ-UHFFFAOYSA-N). This molecule shares its empirical formula (C10H12ClNO) with positional or structural isomers; unambiguous analytical identification requires matching the full IUPAC structure, CAS number (1049677-59-9), and spectroscopic profile.
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), 3-CMC is indexed within the Cathinone derivatives structural group. As a substituted beta-ketone (cathinone derivative), this compound requires strict analytical verification and has documented contraindications with MAOIs, serotonergic agents, and other stimulants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- Riksdagen — Förordning (1999:58) om förbud mot vissa hälsofarliga varor — Sveriges riksdag (2026-11-12)